Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy.
Tumor necrosis factor-alpha inhibitors are important adjunctive therapies for rheumatologic diseases. These agents increase the risk for granulomatous disease. We present a case of a woman with severe rheumatoid arthritis on infliximab who developed multiple nodular skin lesions. Biopsies grew Mycobacterium marinum. New lesions developed through therapy, necessitating surgical debulking.
Danko
Janine R
JR
Infectious Diseases Directorate, Viral/Rickettsial Diseases Department, Naval Medical Research Center, 503 Robert Grant Ave,Room 3N25, Silver Spring, MD 20910, USA. janine.danko@med.navy.mil
Gilliland
William R
WR
Miller
R Scott
RS
Decker
Catherine F
CF
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069285:Infliximab; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000209:etiology* / Q000276:immunology; D019910:Mycobacterium marinum; D017192:Skin Diseases, Bacterial / Q000175:diagnosis / Q000209:etiology* / Q000382:microbiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab